ID
34016
Beschreibung
Study ID: 103974 (primary study) Clinical Study ID: 103974 Study Title: Demonstrate non-inferiority of Men-C immune response of Hib-MenC with Infanrix™-IPV versus a licensed Men-C vaccine with Pediacel™ when given at 2, 3, 4 months and the immunogenicity of Hib-MenC when given as a booster dose at 12-15 months Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00258700 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine Trade Name: BIO HIB-MENC-TT; Menitorix Study Indication: Haemophilus influenzae type b; Neisseria Meningitidis
Stichworte
Versionen (1)
- 11.01.19 11.01.19 -
Rechteinhaber
GSK group of companies
Hochgeladen am
11. Januar 2019
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Primary & Booster Immunogenicity of Hib-MenC vs a Licensed Men-C Vaccine - 103974
Visit 6: Eligibility Check, Laboratory Test
- StudyEvent: ODM
Beschreibung
Check for Study Continuation
Beschreibung
Did the subject return for Visit 6?
Datentyp
boolean
Beschreibung
If No, please tick ONE most appropriate reason
Datentyp
text
Beschreibung
If Other, please specify
Datentyp
text
Beschreibung
If SAE, record the SAE number
Datentyp
integer
Beschreibung
If non-SAE, please record the AE number
Datentyp
integer
Beschreibung
Please tick who took the decision
Datentyp
text
Beschreibung
Elimination Criteria During The Study
Beschreibung
If any of the criteria become applicable during the study, it will not require withdrawal of the subject from the study but may determine a subject's evaluability in the according-to-protocol (ATP) analysis.
Datentyp
text
Beschreibung
1. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period
Datentyp
text
Beschreibung
2. Chronic administration (defined as more than 14 days) or immunodepressants or other imminodefying drugs during the study period.
Datentyp
text
Beschreibung
3. Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after
Datentyp
text
Beschreibung
4. Administration of immunoglobulins and/or any blood products during the study period
Datentyp
text
Beschreibung
Laboratory Tests - Blood
Ähnliche Modelle
Visit 6: Eligibility Check, Laboratory Test
- StudyEvent: ODM
Keine Kommentare